Are we too small to work with AGENCY?
Probably not. We work with founder-led companies pre-revenue through to enterprise pharma. The question is not size, it is stage. If your problem is commercial (you are ready to sell, you just need the system to do it), we are a fit. If you are pre-product and pre-evidence, you need a clinical advisor more than you need us.
For Founders →
Are we too enterprise?
Unlikely. We work with UK subsidiaries of global med-tech, pharma brands with global regulatory envelopes, and platforms with multi-market teams. Our constraint is not scale, it is focus. We take on engagements we can materially move the needle on. If the engagement would be a governance exercise with no decision-making authority, we will say so.
For Enterprise →
Do you work with pre-launch products or only approved ones?
Both. A material share of our work is pre-launch product positioning, launch readiness, and market entry. The 3 E's framework is specifically designed for the pre-launch window. If you are still years from approval, we can still do market-shaping work, but we will suggest a phased engagement that matches where you are.
Product Launch Excellence →
We already have a marketing team. Will you conflict with them?
Rarely. We are most useful when we plug into an existing team, fill a specific capability gap (launch readiness, patient marketing compliance, sales enablement, content at scale), and leave cleanly when the gap is filled. We do not replace marketing teams. We extend them. The clients we stay with longest are the ones where the internal team is strong and we play to a defined scope inside it.
Do you work internationally?
Yes. UK-based, global remit. Recent work spans the UK, Germany, Sweden, France, Italy, Ireland, the Netherlands, the United States, Australia, and several EMEA markets for patient-side campaigns. For heavily-regulated markets we work with local regulatory partners where their expertise matters more than ours.
Do you only work in healthcare?
Yes. Twenty years of commercial experience inside operating theatres, procurement meetings, and healthcare boardrooms. The methodology would transfer to other regulated markets in theory, but we deliberately do not dilute the focus. A generalist is the last thing healthcare clients actually need.